UNITED STATES

SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE


SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2012

June 30, 2013

OR

[ ] TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE


SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NO. 0-17629

ADM TRONICS UNLIMITED, INC.

 (Exact
(Exact name of registrant as specified in its charter)

Delaware
Delaware  
22-1896032
(State or Other Jurisdiction
(I.R.S. Employer
of Incorporation or organization)
22-1896032
(I.R.S. Employer
Identification Number)

224-S Pegasus Ave., Northvale, New Jersey 07647


(Address of Principal Executive Offices)

Registrant's Telephone Number, including area code: (201) 767-6040

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:  YES [X] NO [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES [X] NO [ ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]                                                                                                                                                Accelerated filer [ ]

Non-accelerated filer [ ] (Do not check if a smaller reporting company)                                                                 Smaller reporting company [X]

Large accelerated filer [ ]  

Accelerated filer [ ]

Non-accelerated filer [ ] (Do not check if a smaller reporting company)  

Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES [ ] NO [X]

YES [ ] NO [X]

State the number of shares outstanding of each of the Issuer's classes of common equity, as of the latest practicable date:

56,939,537 shares of Common Stock, $.0005 par value, as of FebruaryAugust 19, 2013.

1

 

ADM TRONICS UNLIMITED, INC., AND SUBSIDIARIES

INDEX

Part I - Financial Information

Page Number

     
INDEX
Page Number
Part I - Financial Information
     
Item 1.Condended Consolidated Financial Statements:  
     

Item 1.

Condended Consolidated Financial Statements:

  Condensed Consolidated Balance Sheet - December 31, 2012 (unaudited) and March 31, 2012 3
     
  

Condensed Consolidated Statements of Operations for the threeBalance Sheet - June 30, 2013 (unaudited) and nine months ended DecemberMarch 31, 2012 and 2011 (unaudited)2013

3

 4
     
  

Condensed Consolidated Statements of Operations for the three months ended June 30, 2013 and 2012 (unaudited)

4

Condensed Consolidated Statements of Cash Flowfor the ninethree months ended December 31,June 30, 2013 and 2012 and 2011 (unaudited)

5

 5
     
  

Notes to the Condensed Consolidated Financial Statements (unaudited)

6

     

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

11

     

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

14

     

Item 4.

Controls and Procedures

15

14

     

Part II - Other Information

     
Item 1.Legal Proceedings 15

Item 1.

Legal Proceedings

14

     
Item 1A.Risk Factors 15

Item 1A.

Risk Factors

14

     

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

15

14

     

Item 3.

Defaults Upon Senior Securities

15

14

     
Item 4.Other Information 15

Item 4.

Other Information

14

     
Item 5.Exhibits 

Item 5.

Exhibits

15

 

2

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

  

June 30,

  

March 31,

 
  

2013

  

2013

 
  

(Unaudited)

     

ASSETS

        
         

Current assets:

        

Cash and cash equivalents

 $31,844  $105,087 

Accounts receivable, net of allowance for doubtful accounts of $500 for each of the periods

  138,533   159,126 

Inventories

  199,649   121,993 

Prepaid expenses and other current assets

  29,220   20,320 

Restricted cash

  232,086   231,782 
         

Total current assets

  631,332   638,308 
         

Property and equipment, net of accumulated depreciation of $63,024 and $53,574, respectively

  12,546   14,292 
         

Inventories - long-term portion

  56,630   113,935 

Secured convertible note receivable, including interest of $17,747 and $16,700, respectively

  59,747   58,700 

Advances to related parties

  11,916   11,916 

Intangible assets, net of accumulated amortization of $116,061 and $113,398, respectively

  52,087   54,750 

Other assets

  15,834   15,834 

Total other assets

  208,760   269,427 
         

Total assets

 $840,092  $907,735 
         

LIABILITIES AND STOCKHOLDERS' EQUITY

        
         

Current liabilities:

        

Note payable - bank

 $144,990  $147,990 

Accounts payable

  188,750   186,373 

Accrued expenses and other current liabilities

  385,063   385,845 

Total current liabilities

  718,803   720,208 
         

Total liabilities

  718,803   720,208 
         

Stockholders' equity:

        

Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding

  -   - 

Common stock, $0.0005 par value; 150,000,000 authorized, 59,939,537 issued and outstanding at June 30, 2013 and March 31, 2013 respectively

  29,970   29,970 

Additional paid-in capital

  32,275,594   32,275,594 

Accumulated deficit

  (32,184,275)  (32,118,037)

Total stockholders' equity

  121,289   187,527 
         

Total liabilities and stockholders' equity

 $840,092  $907,735 

The accompanying notes are an integral part of thesecondensed consolidated financial statements.

  
December 31,
2012
(Unaudited)
  
March 31,
2012
 
 
ASSETS      
       
Current assets:      
Cash and cash equivalents $214,300  $299,156 
Accounts receivable, net of allowance for doubtful accounts of $500 and $329, respectively
  156,451   285,159 
Inventories  280,752   260,632 
Prepaid expenses and other current assets  14,114   26,157 
Restricted cash  231,782   231,455 
         
Total current assets  897,399   1,102,559 
         
Property and equipment, net of accumulated depreciation of $61,264 and $53,574, respectively
  16,052   23,742 
         
Inventories - long-term portion  73,319   42,743 
Secured convertible note receivable  57,664   62,351 
Advances to related parties  22,480   22,480 
Intangible assets, net of accumulated amortization of $110,888 and $101,682, respectively
  57,260   66,466 
Other assets  16,109   16,109 
Total other assets  242,884   233,891 
         
Total assets $1,140,283  $1,336,450 
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
         
Current liabilities:        
Note payable - bank $150,990  $160,000 
Accounts payable  213,070   148,832 
Customer deposit  -   21,023 
Accrued expenses and other current liabilities  401,620   385,935 
Total current liabilities  765,680   715,790 
         
Total liabilities  765,680   715,790 
         
Stockholders' equity:        
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding
  -   - 
Common stock, $.0005 par value; 150,000,000 shares authorized, 56,939,537 shares issued and outstanding at December 31, 2012 and March 31, 2012
  28,470   28,470 
Additional paid-in capital  32,223,097   32,173,097 
Accumulated deficit  (31,876,964)  (31,580,907)
Total stockholders' equity  374,603   620,660 
         
Total liabilities and stockholders' equity $1,140,283  $1,336,450 
 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited)

 
  

2013

  

2012

 
         

Net revenues

 $322,439  $517,239 
         

Cost of sales

  149,202   174,675 
         

Gross Profit

  173,237   342,564 
         

Operating expenses:

        

Research and development

  8,673   9,131 

Selling, general and administrative

  226,956   339,411 

Depreciation and amortization

  4,408   7,403 
         

Total operating expenses

  240,037   355,945 
         

Loss from operations

  (66,800)  (13,381)
         

Other income (expense):

        

Interest income

  1,352   1,443 

Interest expense

  (790)  (1,889)

Total other income (expense)

  562   (446)
         
         

Net loss

 $(66,238) $(13,827)
         

Basic and diluted net loss per common share:

 $(0.00) $(0.00)
         

Weighted average shares of common stock outstanding - basic and diluted

  59,939,537   56,939,537 

The accompanying notes are an integral part of these

condensed consolidated financial statements.

 

3

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSCASH FLOWS

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited)

  
Three months ended
December 31,
  
Nine months ended
December 31,
 
  2012  2011  2012  2011 
             
Net revenues $306,522  $452,943  $1,208,434  $1,344,694 
                 
Cost of sales  148,090   193,553   501,883   599,016 
                 
Gross Profit  158,432   259,390   706,551   745,678 
                 
Operating expenses:                
Research and development  6,999   8,630   25,273   26,630 
Selling, general and administrative  338,510   273,329   958,573   740,098 
Depreciation and amortization  4,780   11,185   16,896   32,645 
                 
Total operating expenses  350,289   293,144   1,000,742   799,373 
                 
Loss from operations  (191,857)  (33,754)  (294,191)  (53,695)
                 
Other income (expense):                
Interest income  1,038   1,484   3,783   4,724 
Interest expense  (1,856)  (1,336)  (5,649)  (3,434)
Total other income (expense)  (818)  148   (1,866)  1,290 
                 
                 
Net Loss $(192,675) $(33,606) $(296,057) $(52,405)
                 
Basic and diluted (loss) per common share: $(0.00) $(0.00) $(0.01) $(0.00)
                 
Weighted average shares of common stock outstanding - basic and diluted  56,939,537   53,939,537   56,939,537   53,939,537 

  

2013

  

2012

 

Cash flows from operating activities:

        

Net loss

 $(66,238) $(13,827)

Adjustments to reconcile net loss to netcash used in operating activities:

        

Depreciation and amortization

  4,408   7,405 

Interest receivable

  (1,047)  (1,196)

Bad debt expense

  -   171 

Accounts receivable

  20,593   9,155 

Inventory

  (20,350)  (5,944)

Prepaid expenses and other current assets

  (8,901)  (2,154)

Accounts payable

  2,377   750 

Customer deposit

  -   (21,023)

Accrued expenses and other current liabilities

  (781)  7,373 

Net cash used in operating activities

  (69,939)  (19,290)
         

Cash flows from investing activities:

        

Repayment from secured convertible debt

  -   8,000 

Restricted cash

  (304)  (175)

Net cash (used in) provided by investing activities

  (304)  7,825 
         

Cash flows used in financing activities:

        

Repayments on note payable - Bank

  (3,000)  (3,000)
         
         

Net cash used in financing activities

  (3,000)  (3,000)
         

Net decrease in cash

  (73,243)  (14,465)
         

Cash and cash equivalents beginning of year

  105,087   299,156 
         

Cash and cash equivalents at end of year

 $31,844  $284,691 
         

Cash paid for:

        

Interest

 $-  $1,889 
 

The accompanying notes are an integral part of these

condensed consolidated financial statements.

 

4

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED  DECEMBER 31, 2012 AND 2011
(Unaudited)
  2012  2011 
Cash flows from operating activities:      
Net loss $(296,057) $(52,405)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
        
Depreciation and amortization  16,896   32,645 
Stock based compensation  50,000   - 
Interest receivable  (3,313)  (3,767)
Bad debt expense  171   - 
Increase (decrease) in cash flows as a result of changes in assets and liabilities balances:     
Accounts receivable  128,537   (57,929)
Inventory  (50,696)  (131,833)
Prepaid expenses and other current assets  8,948   (39,212)
Accounts payable  67,333   21,593 
Customer deposit  (21,023)  108,751 
Accrued expenses and other current liabilities  15,685   112,921 
Net cash used in operating activities  (83,519)  (9,236)
         
Cash flows from investing activities:        
Repayment from related party  -   2,936 
Payment for equipment costs  -   (2,296)
Collections from secured convertible note  8,000   - 
Payment for patents and trademark costs  -   (3,584)
Restricted cash  (327)  (720)
Net cash provided by (used in) investing activities  7,673   (3,664)
         
Cash flows from financing activities:        
Repayments on note payable - Bank  (9,010)  (9,000)
Repayments on note payable - Other  -   (13,900)
         
Net cash used in financing activities  (9,010)  (22,900)
         
Net decrease in cash  (84,856)  (35,800)
         
Cash and cash equivalents beginning of period  299,156   155,149 
         
Cash and cash equivalents at end of period $214,300  $119,349 
         
Cash paid for:        
Interest $2,115  $3,056 
         
Supplemental disclosures of non-cash investing and financing activities:     
Accrued interest on note receivable $3,313  $3,767 
Increase in prepaid insurance and accounts payable $3,095  $8,466 
The accompanying notes are an integral part of these
condensed consolidated financial statements.
5
ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2012

JUNE 30, 2013

(Unaudited)

NOTE 1 - ORGANIZATIONAL MATTERS

ADM Tronics Unlimited, Inc. ("we", "us", the “Company" or "ADM"), was incorporated under the laws of the state of Delaware on November 24, 1969. We are authorized under our Certificate of Incorporation to issue 150,000,000 common shares, with $.0005 par value, and 5,000,000 preferred shares with $.01 par value.

The accompanying condensed consolidated financial statements as of December 31, 2012June 30, 2013 (unaudited) and March 31, 20122013 and for the three month period ended June 30, 2013 and nine month periods ended December 31, 2012 and 2011 (unaudited) have been prepared by ADM pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) including Form 10-Q and Regulation S-X. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements and the information included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the audited financial statements and explanatory notes for the year ended March 31, 20122013 as disclosed in our annual report on Form 10-K for that year . The results of the three and nine months ended December 31, 2012June 30, 2013 (unaudited) are not necessarily indicative of the results to be expected for the pending full year ending March 31, 2013.

2014.

NATURE OF BUSINESS

We are a manufacturing and engineering concern whose principal lines of business are the production and sale of chemical products and the manufacture and sale of electronics. On July 17, 2009, we purchased the assets of Antistatic Industries of Delaware Inc., (“Antistatic”) a company involved in the research, development and manufacture of water-based and proprietary electrically conductive paints, coatings and other products and accessories which can be used by electronics, computer, pharmaceutical and chemical companies to prevent, reduce or eliminate static electricity.


The Company is a corporation that was organized under the laws of the State of Delaware on November 24, 1969. Our operations are conducted through ADM Tronics Unlimited, Inc. ("ADM") and its subsidiaries, Pegasus Laboratories, Inc. ("Pegasus"), Sonotron Medical Systems, Inc. ("SMI") and Action Industries Unlimited LLC (“Action”). As of July 14, 2011, ADM owned approximately 100%, 94% and 100% of the outstanding capital stock of Pegasus, SMI and Action, respectively. On April 1, 2012 Pegasus ceased operations and its assets were transferred to the Company. On April 1, 2013 Action ceased operations and its assets were transferred to the Company. In addition, the Company owns a minority interest in Montvale Technologies, Inc, (formerly known as Ivivi Technologies, Inc.) (“ITI”), which until October 18, 2006 was operated as a subsidiary of the Company. ITI was deconsolidated as of October 18, 2006 upon the consummation of ITI’s initial public offering, as we no longer owned a majority of the outstanding common stock of ITI and do not control ITI’s operations, but can exert significant influence based on the percentage of ITI’s stock owned by us. As a result, our investment in ITI from October 18, 2006 through March 31, 2008 was reported under the equity method of accounting. Since April 1, 2008, we report our investment in ITI at fair value. We owned approximately 28.9% of the outstanding capital stock of ITI. On February 12, 2010 substantially all of the assets of ITI were sold to Ivivi Health Sciences, LLC (“IHS”) an unaffiliated entity controlled by ITI’s former Chairman of the Board. Concurrent with such asset sale, the Company entered into agreements with IHS for services related to engineering and regulatory matters, and the previous manufacturing agreement with ITI was assigned to IHS.

Our chemical product line is principally comprised of water-based chemical products used in the food packaging and converting industries, and anti-static conductive paints, coatings and other products. These products are sold to customers located in the United States, Australia, Asia and Europe. ElectronicsElectronic equipment is manufactured in accordance with customer specifications on a contract basis. Our electronic device product line consists principally of proprietary devices used in diagnostics and therapeutics of humans and animals and, through our Action Industries, Unlimited, LLC subsidiary (“Action”), electronic controllers for spas and hot tubs. These products are sold to customers located principally in the United States. We are registered with the FDA as a contract manufacturing facility and we manufacture medical devices for customers in accordance with their designs and specifications. We also provide research, development and engineering services to customers. Our Sonotron Medical Systems, Inc. subsidiary is involved in medical electronic therapeutic technology and our Pegasus Laboratories, Inc. (“Pegasus”) is involved in topical dermatological products.

As of April 1, 2012 and April 1 2013, Pegasus and Action, respectively, ceased operations and all assets were transferred to the Company.

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The unaudited condensed consolidated financial statements include the accounts of ADM Tronics Unlimited, Inc. and its wholly owned subsidiaries Sonotron, Action Industries Unlimited LLC (AIU)(through March 31, 2013), Sonotron Medical Systems, Inc. (SMS) and Pegasus Laboratories, Inc. (PLI)(through March 31, 2012). All significant intercompany balances and transactions have been eliminated in consolidation.

USE OF ESTIMATES

These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and, accordingly, require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. Significant estimates made by management include expected economic life and value of our medical devices, reserves, deferred tax assets, valuation allowance, impairment of long lived assets, fair value of equity instruments issued to consultants for services, and fair value of equity instruments issued to others, option and warrant expenses related to compensation to employees and directors, consultants and investment banks, allowance for doubtful accounts, and warranty reserves. Actual results could differ from those estimates.

6

FAIR VALUE OF FINANCIAL INSTRUMENTS


For certain of our financial instruments, including accounts receivable, inventories, accounts payable, accrued expenses and notes payable - other,bank, the carrying amounts approximate fair value due to their relatively short maturities.


CASH AND EQUIVALENTS


Cash equivalents are comprised of certain highly liquid investments with maturities of three months or less when purchased. We maintain ourOur cash in bank, depositis maintained in accounts, which at times, may exceed federally insured limits. We have not experienced any losses to date as a result of this policy.


REVENUE RECOGNITION


CHEMICAL PRODUCTS:


Revenues are recognized when products are shipped to end users. Shipments to distributors are recognized as sales where no right of return exists.


ELECTRONICS:


We recognize revenue from the sale of our electronic products when they are shipped to the purchaser.  Shipping and handling charges and costs have been de minimis. We offer a limited 90 day warranty on our electronics products and a limited 5 year warranty on our electronic controllers for spas and hot tubs. Historically, the amount of warranty revenue included in the sales of our electronic products has been de minimis. We have no other post shipment obligations and sales returns have been de minimis.obligations. Based on prior experience, no amounts have been accrued for potential warranty costs and suchactual costs were less than $500, for the three and nine months ended December 31, 2012June 30, 2013 and 2011.


2012. For contract manufacturing, revenues are recognized after shipment of the completed products.

ENGINEERING SERVICES:


Pursuant to a Master Services Agreement with Ivivi Health Sciences, LLC (IHS), ADM provides

We provide certain engineering services, including research, development, quality control and quality assurance services along with regulatory compliance services, warehouse fulfillment services and network administration services including hardware and software services. Under the terms of the Agreement, the Company agrees to serveWe recognize revenue from engineering services as the exclusive manufacturer of all current and future medical and non-medical electronic devices or products sold or rented by IHS.


RESEARCH AND DEVELOPMENT COSTS

Research and development costs consist of expenditures for the research and development of patents and technology whichservices are not capitalizable. Our research and development costs consist mainly of labor costs in developing new products.

provided.

WARRANTY LIABILITIES


The Company’s provision for estimated future warranty costs is based upon historical relationship of warranty claims to sales. Based upon historical experience, the Company has concluded that no warranty liability is required as of the balance sheet dates. However, the Company periodically reviews the adequacy of its product warranties and will record an accrued warranty reserve if necessary.


RESTRICTED CASH


Restricted cash represents funds on deposit with a financial institution that secure the bank note payable.


NET LOSS PER SHARE


The Company computes basic loss per share by dividing the Company's net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share excludes potential common shares if the effect is anti-dilutive. Diluted loss per share is determined in the same manner as basic loss per share except that the number of shares is increased assuming exercise of dilutive stock options and warrants using the treasury stock method. As the Company had a net loss for all periods presented, the impact of the assumed exercise of the stock options is anti-dilutive and as such, these amounts have been excluded from the calculation of diluted loss per share. For the three and nine month periods ended December 31,June 30, 2013 and 2012, and 2011, there were no5,600,000 and 0 common stock equivalent shares.


shares, respectively. 

RECENT ACCOUNTING PRONOUNCEMENTS


Management does not believe that any other recently issued, but not yet effective accounting pronouncement, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

7

NOTE 3 - INVENTORY


Inventory at December 31, 2012 (unaudited)June 30, 2013 consisted of the following:

  Current  Long Term  Total 
Raw materials $223,658  $68,408  $292,066 
Finished Goods  57,094   4,911   62,005 
  $280,752  $73,319  $354,071 

  

Current

  

Long Term

  

Total

 

Raw materials

 $186,011  $27,651  $213,662 

Finished Goods

  13,638   28,979   42,617 
  $199,649  $56,630  $256,279 

Inventory at March 31, 20122013 consisted of the following:

  Current  Long Term  Total 
Raw materials $204,367  $38,555  $242,922 
Finished Goods  56,265   4,188   60,453 
  $260,632  $42,743  $303,375 

  

Current

  

Long Term

  

Total

 

Raw materials

 $71,900  $92,781  $164,681 

Finished Goods

  50,093   21,154   71,247 
  $121,993  $113,935  $235,928 

The Company values its inventories at the first in, first out ("FIFO") method at the lower of cost or market.

NOTE 4 – SECURED CONVERTIBLE NOTE RECEIVABLE


On June 4, 2009 the Company, invested in Wellington Scientific, LLC (“Wellington”), which has rights to an electronic uroflowmetry diagnostic medical device technology.  The Company invested a total of $50,000, with $10,000 provided in cash, and $40,000 in services to Wellington. Wellington Scientific, LLC ("Wellington"). Wellington, which has rights to an electronic uroflowmetry diagnostic medical device technology, issued a convertible note to the Company for a principal amount of $50,000 with an interest rate of 10% due at various dates through July 15, 2012.  The total of the note receivable and accrued interest at December 31, 2012June 30, 2013 and March 31, 20122013 was $57,664$59,747 and $62,351,$58,700, respectively. At the option of the Company, the Note is convertible in whole or in part, into equity of Wellington.

The conversion price, and the resulting equity ownership percentage in Wellington, is determined by dividing the cash value of principal and accrued interest by $2,000,000.


In August 2012, the Company filed a civil suit in the Superior Court of New Jersey against defendants Wellington Scientific LLC (“Wellington”) and Peter F. Lordi, demanding payment of the convertible note receivable from Wellington in the amount of $50,000 (plus accrued interest). The Company is suing for breach of contract, fraud in the inducement, and other claims. Since this civil suit is in the early stages of litigation, its ultimate outcome cannot be predicted with certainty at this time.


As of FebruaryAugust 19, 2013, the loan has not yet been repaid.

 

8

NOTE 5 -INTANGIBLE ASSETS


Intangible assets are being amortized using the straight line method over periods ranging from 3-15 years with a weighted average remaining life of approximately 7.4 years.

  December 31, 2012  March 31, 2012 
  Cost 
 
 
 
 Weighted Average Amortization Period
(years)
 Accumulated Amortization  Net Carrying Amount  Cost 
 Weighted Average Amortization Period
(years)
 Accumulated Amortization  Net Carrying Amount 
Patents & Trademarks $82,702  15 $(63,916) $18,786  $82,702  15 $(62,464) $20,238 
Formulas  25,446  15  (6,020)  19,426   25,446  15  (4,595)  20,851 
Non-Compete Agreement  50,000  7  (30,952)  19,048   50,000  7  (25,595)  24,405 
Customer List  10,000  3  (10,000)  -   10,000  3  (9,028)  972 
  $168,148   $(110,888) $57,260  $168,148   $(101,682) $66,466 

  

June 30, 2013

  

March 31, 2013

 
  

Cost

 

Weighted Average Amortization Period (years)

 

Accumulated Amortization

  

Net Carrying Amount

  

Cost

 

Weighted Average Amortization Period (years)

 

Accumulated Amortization

  

Net Carrying Amount

 

Patents & Trademarks

 $82,702 

15

 $(64,822) $17,880  $82,702 

15

 $(64,369) $18,333 

Formulas

  25,446 

15

  (6,715)  18,731   25,446 

15

  (6,291)  19,155 

Non-Compete Agreement

  50,000 

7

  (34,524)  15,476   50,000 

7

  (32,738)  17,262 

Customer List

  10,000 

3

  (10,000)  -   10,000 

3

  (10,000)  - 
  $168,148   $(116,061) $52,087  $168,148   $(113,398) $54,750 

Amortization expense was $9,206$2,663 and $21,548$3,565 for the ninethree months ended December 31,June 30, 2013 and 2012, and 2011, respectively.

Estimated aggregate future amortization expense related to intangible assets is as follows:

 2013  $2,512  
 2014   10,650  
 2015   10,601  
 2016   5,890  
 2017   2,914  
  Thereafter   24,693  
    $57,260  

2014

 $8,166 

2015

  10,778 

2016

  6,068 

2017

  3,092 

2018

  3,092 

Thereafter

  20,891 
  $52,087 

NOTE 6 - CONCENTRATIONS

During the three month period ended December 31, 2012, threeJune 30, 2013, two customers accounted for 41%35% of our revenue. As of December 31, 2012,June 30, 2013, three customers represented approximately 55%53% of our accounts receivable.


During the three month period ended December 31, 2011,June 30, 2012, three customers accounted for 65%50% of our revenue. As of December 31, 2011, twoJune 30, 2012, three customers represented approximately 85%56% of our accounts receivable.


During the nine month period ended December 31, 2012, three customer accounted for 39% of our revenue. During the nine month period ended December 31, 2011, two customers accounted for 36% of our revenue.

The Company’s customer base is comprised of foreign and domestic entities with diverse demographics. Revenues from foreign customers represented $56,008$46,954 of net revenue or 18.3%14.6% for the three months ended December 31, 2012June 30, 2013 and $151,622$37,080 of net revenue or 12.5% for the nine months ended December 31, 2012.


Revenues from foreign customers represented $30,741 of net revenue or 6.8%7.2% for the three months ended December 31, 2011June 30, 2012. As of June 30, 2013 and $153,539 of net revenue or 11.4% of net revenue for the nine months ended December 31, 2011.

Accounts2012, accounts receivable includes approximately $4,000 and $20,000, respectively, from foreign entities as of December 31, 2012 and March 31, 2012 were $24,232 and $16,198, respectively.
9
customers.

NOTE 7 - SEGMENT INFORMATION

Information about segments is as follows:

  

Chemical

  

Electronics

  

Total

 

Three months ended June 30, 2013

            

Revenue from external customers

 $249,780  $72,659  $322,439 

Segment operating income (loss)

 $70,571  $(106,085) $(35,514)
             

Three months ended June 30, 2012

            

Revenue from external customers

 $289,964  $227,275  $517,239 

Segment operating income (loss)

 $65,186  $(54,128) $11,058 
             

Total assets at June 30, 2013

 $654,536  $216,843  $871,379 
             

Total assets at March 31, 2013

 $589,739  $317,996  $907,735 

 
  Chemical  Electronics  Total 
Three months ended December 31, 2012         
Revenue from external customers $266,061  $40,461  $306,522 
Segment operating income (loss) $5,716  $(197,573) $(191,857)
             
Three months ended December 31, 2011            
Revenue from external customers $175,127  $277,816  $452,943 
Segment operating income (loss) $24,381  $(58,135) $(33,754)
             
Nine months ended December 31, 2012            
Revenue from external customers $814,999  $393,435  $1,208,434 
Segment operating income (loss) $105,780  $(399,971) $(294,191)
             
Nine months ended December 31, 2011            
Revenue from external customers $720,363  $624,331  $1,344,694 
Segment operating income (loss) $77,930  $(131,625) $(53,695)
             
Total assets at December 31, 2012 $737,687  $402,596  $1,140,283 
             
Total assets at March 31, 2012 $540,349  $796,101  $1,336,450 

NOTE 8 - RELATED PARTY TRANSACTIONS


ADVANCES TO RELATED PARTIES


As of December 31, 2012June 30, 2013 and March 31, 2012,2013, ADM was owed $0$-0- from advances made to an officer. No advances have beenDuring the three months ended June 30, 2013, no repayments were made since 2000. The previous balance, now paid in full, had anon the interest rate of 3% per year.accrued on these advances. Total accrued interest was $11,916 at December 31, 2012June 30, 2013 and March 31, 2012 was $22,480 and $22,480,2013, respectively.


NOTE 9 – NOTE PAYABLE, BANK


On August 21, 2008, the Company entered into a note payable with a commercial bank in the amount of $200,000.  This note bears interest at a rate of 2% above the interest rate for the Company’s savings account at this bank and is secured by cash on deposit with the institution, which is classified as restricted cash.  Amounts outstanding under the note are payable on demand, and interest is payable monthly. The principal balance of the note at December 31, 2012June 30, 2013 and March 31, 20122013 was $150,990$144,990 and $160,000,$147,990, respectively.


NOTE 10 – NOTE PAYABLE – OTHER


On July 17, 2009 we purchased the assets of Antistatic Industries of Delaware, Inc. in exchange for cash and a note payable, bearing imputed interest rate of 3.5% per annum. The monthly interest and principal payments were $1,450 and as of December 31, 2012, the note has been fully paid.

NOTE 11 – CUSTOMER DEPOSIT

In July 2011 a customer made a cash deposit of $179,450 in conjunction with- OPTIONS OUTSTANDING

During 2013, ADM Granted an order for 200 units of the Flo-Med device. For the nine months ended December 31, 2012, the balance of the deposit totaling $21,023 was recognized as revenue.

10

NOTE 12 – STOCK OPTIONS

On December 20, 2012, 5,000,000 options were granted to Andre DiMino vesting immediately. The exercise price is $0.005 per share and the expiration date is December 20, 2017. The compensation cost recognized as of December 31, 2012 was $50,000.
A summary of the Company’saggregate 5,600,000 stock options activity is as follows:
  Shares  
Weighted Average
Exercise Price
 
       
       
Outstanding - April 1, 2012
  -  $- 
Granted  5,000,000   0.005 
Exercised  -   - 
         
Cancelled, Forfeited, or Expired  -   - 
         
Outstanding - December 31, 2012
  5,000,000  $0.005 
         
Exercisable - December 31, 2012  5,000,000  $0.005 
to employees and consultantsexpiring at various dates through fiscal 2015. The following is a summary of stock options outstanding at December 31, 2012:
 
 
Exercise
Price
 
  
 
 
Number
Outstanding
 
  
 
Weighted
 Average
 Remaining
 Contractual
Life
(in Years)
 
  
 
 
Weighted
 Average
 Exercise
 Price
 
  
 
Number
Exercisable
 
 
              
$0.005   5,000,000   4.97  $0.005   5,000,000 

The fair value of the optionshad various exercise prices and were determined by using the Black Scholes methodfullyvested at the date of grant of thegrant. The options based onwere valued at $55,997 using Black Scholes option pricingmodel with the following assumptions ranges: (1)assumptions: risk free interest rate of 0.77%  (2) dividend yield4.9%, volatility of 0%; (3) volatility factor of 430%; and (4) an expected414%, estimateduseful life of the1.5 years and dividend rate of 0%. The following table summarizes information on allcommon share purchas options of 2.5 years.

The weighted average fair value options granted was $0.005 per share during 2012.  There was $0 of total unrecognized compensation cost related to share-based compensation arrangementsissued by us as of December 31,June 30, 2013 and 2012.


  2013  

2012

 
  

# of Shares

  

Weighted

Average

Exercise Price

  

# of Shares

  

Weighted

Average

Exercise Price

 
                 

Outstanding, beginning of year

  5,600,000  $0.01   -  $- 
                 

Issued

  -   -   -   - 
                 

Expired

  -   -   -   - 
                 

Outstanding, June 30

  5,600,000  $0.01   -  $- 
                 

Exercisable, June 30

  5,600,000  $0.01   -  $- 
  

NOTE 1311 – COMMITMENTS


We lease our office and manufacturing facility under a non-cancelable operating lease, which expires on June 30, 2019. The Company’s future minimum lease commitment at June 30, 2013 is as follows:

Period

 

Per year

 

2014

 $77,016 

2015

 $104,625 

2016

 $104,625 

2017

 $104,625 

2018

 $104,625 

Thereafter

 $26,156 
  $521,672 

Rent and real estate tax expense for all facilities for the three months ended June 30, 2013 and 2012 was approximately $31,000 and $27,000, respectively.

MASTER SERVICES AGREEMENT


On February 12, 2010, ADM agreed to provide certain services to Ivivi Health Sciences, LLC (IHS) pursuant to a Master Services Agreement, as described below:

●

We provided IHS with engineering services, including quality control and quality assurance services along with regulatory compliance services, warehouse fulfillment services and network administrative services including hardware and software services;

●

We were paid at the rate of $26,000 per month by IHS for these services; in June 2010, it was agreed that IHS would pay approximately $11,000 for June 2010 and approximately $5,000 per month thereafter for reduced services performed by ADM. In May, 2011 IHS agreed to pay ADM approximately $16,800 per month for increased services for one (1) year and then on a month-to-month basis. In August 2012 IHS agreed to pay ADM approximately $6,000 per month for reduced services on a month-to-month basis. Pursuant to this agreement, revenues from engineering services to IHS for the three months ended June 30, 2013 and 2012 were $19,096 and $52,034 respectively.


• we provided IHS with engineering services, including quality control and quality assurance services along with regulatory compliance services warehouse fulfillment services and network administration services including hardware and software services;
• we were paid at the rate of $26,000 per month by IHS for these services; in June 2010, it was agreed that IHS would pay approximately $11,000 for June 2010 and approximately $5,000 per month thereafter for reduced services performed by ADM. In May 2011, IHS agreed to pay ADM approximately $16,800 per month for increased services, which decreased to approximately $6,000 in August 2012.  Pursuant to this agreement, revenues from engineering services to IHS for the nine months ended December 31, 2012 and 2011 were $124,530 and $156,857, respectively.

For the three months ended December 31, 2012 and 2011, revenue was $19,439 and $52,116, respectively.
11

MANUFACTURING AGREEMENT


Under the terms of the February 12, 2010 manufacturing agreement with IHS, ADM has agreed to serve as the exclusive manufacturer of all current and future medical and nonmedicalnon-medical electronic and other electronic devices or products to be sold or rented by IHS. For each product that ADM manufactures, IHS pays ADM an amount equal to 120% of the sum of (i) the actual, invoiced cost for raw materials, parts, components or other physical items that are used in the manufacture of the product.product and actually purchased for such entity by ADM, if any, plus (ii) a labor charge based on ADM'sADM’s standard hourly manufacturing labor rate, which ADM believes is more favorable than could be attained from unaffiliated third parties. Under the terms of the agreement,Agreement, if ADM is unable to perform its obligations to IHS under the manufacturing agreement or is otherwise in breach of any provision of the manufacturing agreement, IHS has the right, without penalty, to engage third parties to manufacture some or all of its products. In addition, if IHS elects to utilize a third-party manufacturer to supplement the manufacturing being completed by ADM, IHS has the right to require ADM to accept delivery of its products from these third partythird-party manufacturers, finalize the manufacture of the products to the extent necessary andto ensure that the design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process have been met.


Pursuant to the manufacturing agreement, sales of finished goods to IHS for the nine months ended December 31, 2012 and 2011 were $90,768 and $108,613, respectively. Sales were $22,275 and $65,191 for the three months ended December 31,June 30, 2013 and 2012 were $41,189 and 2011,$65,883, respectively.


NOTE 1412 – SUBSEQUENT EVENTS


On January 25, 2013

We evaluated all subsequent events from the Company entered into an agreement with a consultant to provide advicedate of the balance sheet through the issuance date of this report and consulting service regarding business strategies, strategic relationships, acquisitions and other areas mutually determined until December 31, 2014.  In consideration,that there were no events or transactions occurring durring the consultant purchased 3,000,000 shares of common stock at par value resultingsubsequent event reporting period which require recognition or disclosure in cash receipts of $1,500 to the Company.

condensed Financial statements. 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our operations and financial condition should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q.


FORWARD-LOOKING STATEMENTS


This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the "safe harbor" provisions under section 21E of the Securities and Exchange Act of 1934 and the Private Securities Litigation Act of 1995. We use forward-looking statements in our description of our plans and objectives for future operations and assumptions underlying these plans and objectives. Forward-looking terminology includes the words "may", "expects", "believes", "anticipates", "intends", "forecasts", "projects", or similar terms, variations of such terms or the negative of such terms. These forward-looking statements are based on management's current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in such forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this Form 10-Q to reflect any change in our expectations or any changes in events, conditions or circumstances on which any forward-looking statement is based. Factors which could cause such results to differ materially from those described in the forward-looking statements include those set forth under "Item. 1 Description of Business – Risk Factors" and elsewhere in or incorporated by reference into our Annual Report on Form 10-K for the year ended March 31, 2012.


2013.

CRITICAL ACCOUNTING POLICIES


REVENUE RECOGNITION:


CHEMICALS:


Revenues are recognized when products are shipped to end users.  Shipments to distributors are recognized as sales where no right of return exists.

ELECTRONICS:


ELECTRONICS:

We recognize revenue from the sale of our electronic products when they are shipped to the purchaser. Revenue from the sale of the electronics we manufacture is recognized upon shipment of product. Shipping and handling charges and costs are de minimis. We offer a limited 90 day warranty on our electronics products and a limited 5 year warranty on our electronic controllers for spas and hot tubs. Historically, the amount of warranty revenue included in the sales of our electronic products have been de minimis. We have no other post shipment obligations and sales returns have been de minimis.


WARRANTY LIABILITIES


We offer a limited 90 day warranty on our electronics products and a 5 year limited warranty on all of our electronic controllers for spas and hot tubs sold through Action.  This product lines’ past experience has resulted in de minimis costs associated with warranty issues.  Therefore, no warranty liabilities have yet been recorded. Accordingly, management has not accrued any liability for future expenses as management has deemed such costs to be de minimus.

12

USE OF ESTIMATES:


Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the US. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to reserves, deferred tax assets and valuation allowance, impairment of long-lived assets, fair value of equity instruments issued to consultants for services and fair value of equity instruments issued to others. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above described items, are reasonable.

BUSINESS OVERVIEW


ADM is a corporation that was organized under the laws of the State of Delaware on November 24, 1969. During the yearsthree months ended March 31,June 30, 2013 and 2012, and 2011, our operations wereare conducted through ADM itselfTronics Unlimited, Inc. ("ADM") and its subsidiaries, Pegasus Laboratories, Inc. (PLI) and Sonotron Medical Systems, Inc. (SMS("SMI") and Action Industries Unlimited LLC (“AIU”("Action"). On April 1, 2013 Action ceased operations and its assets were transferred to the Company. In addition, the Company owns a minority interest in Montvale Technologies, Inc,Inc. (formerly known as Ivivi Technologies, Inc.) (“ITI”("ITI"), which until October 18, 2006 was operated as a subsidiary of the Company. ITI was deconsolidated as of October 18, 2006 upon the consummation of ITI’sITI's initial public offering. Our investment in ITI from October 18, 2006 through March 31, 2008 was reported under the equity method of accounting. Since April 1, 2008 we reported our investment in ITI at fair value. As reported by ITI, on February 12, 2010 all of ITI’s assets were acquired by IHS, an unaffiliated entity controlled by ITI’s former Chairman of the Board. Concurrent with such asset sale, the Company entered into agreements with IHS for services related to engineering and regulatory matters, and the previous manufacturing agreement with ITI was assigned to IHS.


In 2009, we invested in Wellington Scientific, LLC (“Wellington”) which has rights to an electronic uroflowmetry diagnostic medical device technology. During the year ended March 31, 2012, we completed development of a new version of the device (Flo-Med device) for compliance with FDA and international standards and created the required documentation for distribution of this product in the US. In July, 2011 an order was received from a distributor for approximately $740,000 including a 25% cash deposit for the purchase of the Flo-Med device and related disposables. Production of the Flo-Med device and disposables continued during the period and the complete order was fulfilled during the quarter ended June 30, 2012.


We are a technology-based developer and manufacturer of diversified lines of products in the following four areas: (1) environmentally safe chemical products for industrial use, (2) electronic products for numerous industries, including therapeutic non-invasive electronic medical devices and electronic controllers for spas and hot tubs, (3) cosmetic and topical dermatological products and (4) Antistatic paint and coatings products. We have historically derived most of our revenues from the development, manufacture and sale of chemical products, and, to a lesser extent, from our electronics and topical dermatological products. Our Electronics segment includes our AIU and SMS subsidiaries, and our Chemical segment includes our PLI subsidiary.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 2012JUNE 30, 2013 AS COMPARED TO DECEMBER 31, 2011

JUNE 30, 2012

REVENUES

Revenues were $306,522$322,439 for the three months ended December 31, 2012June 30, 2013 as compared to $452,943$517,239 for the three months ended December 31, 2011,June 30, 2012, a decrease of $146,421,$194,800, or 32%38%. The decrease resulted from a decrease in sales to customers in both our electronics division in the amount of $226,978 coupled with an increase in sales in our$154,616 and chemical division in the amount of $90,934 and an increase in sales in our electronics subsidiary, Action, in the amount of $693 and a decrease in sales in our Sonotron division of $11,070.

$40,184.

Gross profit was $158.432,$204,523, or 51.7%63.4%, for the three months ended December 31, 2012June 30, 2013 and $259,390,$342,546, or 57.3%66.2% for the three months ended December 31, 2011.June 30, 2012. Gross profit percentage decreasedincreased in our chemical division 31% though sales and2%,. However, there was a decrease in gross profit increased $90,957 and $10,628 respectively. Gross profit percentagespercentage of 32% in our Antistaticelectronics division decreased 20%mostly due to an overall increasea decrease in costsales of materials, while labor cost percentages increased marginally.$154,616. Gross profit percentages decreased 62% in our electronics division due to a reduction of sales of our Flo-Med product coupled with increases in material and labor costs of 17%.

We are highly dependent upon certain customers to generate our revenues. During the three month period ended December 31, 2012, threeJune 30, 2013, two customers accounted for 41%35% of our revenue. During the three month period ended December 31, 2011,June 30, 2012, three customers accounted for 65%50% of our revenue. TheThe complete loss of or significant reduction in business from, or a material adverse change in the financial condition of any of our customers could cause a material and adverse change in our revenues and operating results.  

 

OPERATING PROFIT / LOSS


Loss from operations for the three months ended December 31, 2012June 30, 2013 was $191,857$66,238 compared to a loss from operations for the three months ended December 31, 2011June 30, 2012 of $33,754.$13,827. Selling, general and administrative expenses increaseddecreased by $65,181,$112,455, or 24%33%, from $273,329$339,411 to $338,510$226,956 mainly due to a stock paymentdecrease of $50,000$47,475 in commissions due to Andre DiMino,reduced sales in our Presidentelectronics division and Chief Executive Officer and an increasea decrease of $63, 801$22,044 in regulatory engineering costs. Cost of sales decreased by $45,463,$25,473, or 23%14.6% from $193,553$174,675 to $148,090,$149,202, due to a decrease in direct material purchases of $49,645 offset by an increase$54,448 coupled with a decrease in laborfreight costs of $7,744.

13
$3,204.

NET LOSS AND NET LOSS PER SHARE

Net loss for the three months ended December 31, 2012June 30, 2013 was $192,674,$66,238, or $0.00 per share, compared to a net loss for the three months ended December 31, 2011June 30, 2012 of $33,606,$13,827 or $0.00 per share. Interest income decreased $446$91 to $1,038$1,352 in the three months ended December 31, 2012,June 30, 2013, from $1,484$1,443 in the three months ended December 31, 2011,June 30, 2012, due to decreased funds invested in a money market account, offset by an increase in accrued interest receivable on a convertible note issued to Wellington.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED DECEMBER 31, 2012 AS COMPARED TO DECEMBER 31, 2011
REVENUES
Revenues were $1,208,434 for the nine months ended December 31, 2012 as compared to $1,344,694 for the nine months ended December 31, 2011, a decrease of $136,260 or 10%.  The decrease resulted from an increase in sales to customers in our antistatic and chemical divisions of $22,438 and $72,198 respectively offset by a decrease in sales in our electronics division of $125,699 and a decreases in our Action and Sonotron subsidiaries of $59,422 and $45,775, respectively
Gross profit was $706,551, or 58%, for the nine months ended December 31, 2012 and $745,678, or 55% for the nine months ended December 31, 2011.  Gross profit percentages decreased in our chemical division and antistatic divisions 1% and 4% respectively. Gross profit percentage increased 6% in our electronics division due the sale of our Flo-Med product during the period ended December 31, 2012.
We are highly dependent upon certain customers to generate our revenues. During the nine month period ended December 31, 2012, three customers accounted for 39% of our revenue. During the nine month period ended December 31, 2011, two customers accounted for 36% of our revenue.  The complete loss of or significant reduction in business from, or a material adverse change in the financial condition of any of our customers could cause a material and adverse change in our revenues and operating results.   
OPERATING LOSS

Loss from operations for the nine months ended December 31, 2012 was $294,192 compared to a loss from operations for the nine months ended December 31, 2011 of $53,695. Selling, general and administrative expenses increased by $218,475 or 30%, from $740,098 to $958,573 mainly due to compensation expense of $50,000 for stock options granted to Andre DiMino, our President and Chief Executive Officer, an increase of $145,186 in regulatory engineering costs and an increase in royalties of $23,240. Cost of sales decreased by $97,133 or 16% from $599,016 to $501,883, due to a decrease in direct material purchases of $121,259 offset by an increase in labor costs of $21,110.

NET LOSS AND NET LOSS PER SHARE
Net loss for the nine months ended December 31, 2012 was $296,057, or $(0.01) per share, compared to a net loss for the nine months ended December 31, 2011 of $52,405, or $(0.00) per share. Interest income decreased $941 to $3,783 in the nine months ended December 31, 2012, from $4,724 in the nine months ended December 31, 2011, due to decreased funds invested in a money market account, offset by an increase in accrued interest receivable on a convertible note issued to Wellington.

LIQUIDITY AND CAPITAL RESOURCES


At December 31, 2012,June 30, 2013, we had cash and cash equivalents of $214,300$31,844 as compared to $299,156$105,087 at March 31, 2012.2013. The $84,856$73,243 decrease was primarily the result of cash used in operations during the ninethree month period in the amount of $83,519,$69,939, cash providedused by investing activities of $7,673$304 and cash used in financing activities in the amount of $9,010.$3,000. Our cash will continue to be used for increased marketing costs, and the related administrative expenses, in order to attempt to increase our revenue.  We expect to have enough cash to fund operations for the next twelve months. Our note payable of $150,990$144,990 at December 31, 2012,June 30, 2013, is secured and collateralized by restricted cash of $231,782.$232,086. This note bears an interest rate of 2% above the rate of the savings account. The interest rate at December 31, 2012June 30, 2013 was 2.20% and is payable upon demand.


Future Sources of Liquidity:


We expect our primary source of cash during fiscal 2013 to be net cash provided by operating activities.

We expect that growth in profitable revenues and continued focus on new customers will enable us to continue to generate cash flows from operating activities. activities during fiscal 2014.

If we do not generate sufficient cash from operations, face unanticipated cash needs or do not otherwise have sufficient cash, we may need to consider the sale of certain intellectual property which does not support the Company’s operations. In addition, we have the ability to reduce certain expenses depending on the level of business operation.

14

Based on current expectations, we believe that our existing cash of $214,300$31,844 as of December 31, 2012 and our net cash provided by operating activitiesJune 30, 2013 and other potential sources of cash will be sufficient to meet our cash requirements. Our ability to meet these requirements will depend on our ability to generate cash in the future, which is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control.

OPERATING ACTIVITIES

Net cash used by operating activities was $83,519$69,939 for the ninethree months ended December 31, 2012,June 30, 2013, as compared to net cash used by operating activities of $9,236$19,290 for the ninethree months ended December 31, 2011.June 30, 2012.  The use of cash during the ninethree months ended December 31, 2012June 30, 2013 was primarily due to net loss of $296,057$66,238 and an increase in operating liabilities of $61,995,$1,596, and ana decrease in net operating assets of $86,789.             


Net$8,658.   

INVESTING ACTIVITIES

For the three months ended June 30, 2013, net cash used by operatingin investing activities was $9,236 for the nine months ended December 31, 2011. The reduction of $364,935 of cash used during the nine months ended December 31, 2011 was primarily$304 due to net loss reduction of $331,619, an increase in accounts receivable of $57,929 and an increase in prepaid expenses of $39,212 offset with an increase in accrued expenses of $112,921 and a deposit payable from a customer in the amount of $108,751.


INVESTING ACTIVITIES

Fordeposits into the nine months ended December 31, 2012, netrestricted cash account.    

Net cash provided by investing activities was $7,673 mainly due to the collection against our secured convertible note. 

Net cash used in investing activities was $3,664$7,825 for the ninethree months ended December 31, 2011,June 30, 2012, mainly as a result of the payments for patents and trademarks and equipment duringreceived on the period.
secured convertible note.

FINANCING ACTIVITIES


For the ninethree months ended December 31,June 30, 2013 and 2012, net cash used forin financing activities was $9,010,$3,000, which was used for repaymentwere repayments on a note from a commercial bank to facilitate our acquisition of AIU.


For the nine months ended December 31, 2011, net cash used for financing activities was $22,900, of which $9,000 was used for repayment on a note from a commercial bank to facilitate our acquisition of AIU and $13,900 was used for repayment of notes payable – other.

OFF BALANCE SHEET ARRANGEMENTS’

We have no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and our investment in ITI. We have no control over the market value of our investment in ITI.

We maintain cash and cash equivalents with FDIC insured financial institutions.

Our sales are materially dependent on a small group of customers, as noted in Note 6 of our financial statements. We monitor our credit risk associated with our receivables on a routine basis. We also maintain credit controls for evaluating and granting customer credit.


ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES


The Company's management, including the Company's principal executive officer and principal financial officer, have evaluated the effectiveness of the Company's "disclosure controls and procedures," as such term is defined in Ru1e 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, (the "Exchange Act"). Based upon their evaluation, the principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the "SEC") (1) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and (2) is accumulated and communicated to the Company'stheCompany's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. During the quarterly period ended December 31,2012,June 30, 2013, there were no changes in the Company's internal control over financial reporting which materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

15

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING

There were no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

In August 2012, the Company filed a civil suit in the Superior Court of New Jersey against defendants Wellington Scientific LLC (“Wellington”) and Peter F. Lordi, demanding payment of the convertible note receivable from Wellington in the amount of $50,000 (plus accrued interest). The Company is suing for breach of contract, fraud in the inducement, and other claims. Since this civil suit is in the early stages of litigation, its ultimate outcome cannot be predicted with certainty at this time.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors contained in our Annual Report on Form 10-K for the year ended March 31, 2012.

2013.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. OTHER INFORMATION

None 

 
None

ITEM 5. EXHIBITS.

(a) Exhibit No.

31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

101.INS**

XBRL Instance

101.SCH**

XBRL Taxonomy Extension Schema

101.CAL**

XBRL Taxonomy Extension Calculation

101.DEF**

XBRL Taxonomy Extension Definition

101.LAB**

XBRL Taxonomy Extension Labels

101.PRE**

XBRL Taxonomy Extension Presentation

** XBRL Instance Document

101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document


information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ADM TRONICS UNLIMITED, INC.
 (Registrant)

ADM TRONICS UNLIMITED, INC.

(Registrant)

   
     
 By:/s/ Andre' DiMino 
  Andre' DiMino, Chief Executive 
  Officer and Chief Financial Officer 

Dated: Northvale, New Jersey
 February 19, 2013
16

Dated:

Northvale, New Jersey

August 19, 2013

15